Skip to main content

Top market strategies for today's pharma landscape

The complexity of turning a new drug into a successful asset remains a hurdle even beyond the coveted FDA approval. As the pharma industry stares down a historic patent cliff, macroeconomic headwinds and challenging R&D costs for increasingly complex medicines, nailing the launch of new medicines has become increasingly critical.

included in this trendline
  • Biogen scores Cannes Festival win with dark humored campaign
  • Is DTC pharma advertising coming to an end?
  • Megablockbusters are the holy grail. Here’s how drugmakers are getting there.
Our Trendlines go deep on the biggest trends. These special reports, produced by our team of award-winning journalists, help business leaders understand how their industries are changing.
Davide Savenije Editor-in-Chief at Industry Dive.